Moderna quarterly sales beat expectations

Moderna (MRNA.O) said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC) advisers to recommend the company's respiratory syncytial virus (RSV) vaccine be considered equal to rival shots launched last year.